BACKGROUND: Claudin-7 (CLDN-7) is a tight junction protein that has been shown overexpressed in several human cancers. We investigated prognostic significance of CLDN-7 overexpression in patients with epithelial ovarian carcinoma (EOC) and its functional role on cell proliferation in ovarian carcinoma cell lines. PATIENTS AND METHODS: CLDN-7 expression was evaluated by real-time RT-PCR and immunohistochemical analysis in 71 patients with EOC. We assessed the association of CLDN-7 expressions with prognosis of the patients including sensitivity to platinum-based chemotherapy. In vitro experiment was performed with and without inhibition of CLDN-7 by its siRNA to evaluate the sensitivity of the human ovarian cancer cells to cisplatin chemotherapy. RESULTS: CLDN-7 transcripts in EOCs were significantly up-regulated compared with normal ovarian tissues (P<0.001). The expression of CLDN-7 protein was observed in majority (69/71, 97.1%) of the EOCs but not in normal ovarian tissues (P<0.001). High CLDN-7 expression in primary tumour correlated with shorter progression-free survival (PFS) of the patients (P=0.005) and poor sensitivity to platinum-based chemotherapy (P=0.024). Moreover, CLDN-7 was highly expressed in 2774 and HeyA8 human ovarian cancer cells and inhibition of CLDN-7 by its siRNA significantly enhanced the sensitivity of 2774 and HeyA8 cells to cisplatin treatment. CONCLUSION: These findings suggest CLDN-7 expression is an independent prognostic factor for PFS and it may play a role in regulating response to platinum-based chemotherapy in the treatment of EOC.
BACKGROUND:Claudin-7 (CLDN-7) is a tight junction protein that has been shown overexpressed in several humancancers. We investigated prognostic significance of CLDN-7 overexpression in patients with epithelial ovarian carcinoma (EOC) and its functional role on cell proliferation in ovarian carcinoma cell lines. PATIENTS AND METHODS: CLDN-7 expression was evaluated by real-time RT-PCR and immunohistochemical analysis in 71 patients with EOC. We assessed the association of CLDN-7 expressions with prognosis of the patients including sensitivity to platinum-based chemotherapy. In vitro experiment was performed with and without inhibition of CLDN-7 by its siRNA to evaluate the sensitivity of the humanovarian cancer cells to cisplatin chemotherapy. RESULTS:CLDN-7 transcripts in EOCs were significantly up-regulated compared with normal ovarian tissues (P<0.001). The expression of CLDN-7 protein was observed in majority (69/71, 97.1%) of the EOCs but not in normal ovarian tissues (P<0.001). High CLDN-7 expression in primary tumour correlated with shorter progression-free survival (PFS) of the patients (P=0.005) and poor sensitivity to platinum-based chemotherapy (P=0.024). Moreover, CLDN-7 was highly expressed in 2774 and HeyA8 humanovarian cancer cells and inhibition of CLDN-7 by its siRNA significantly enhanced the sensitivity of 2774 and HeyA8 cells to cisplatin treatment. CONCLUSION: These findings suggest CLDN-7 expression is an independent prognostic factor for PFS and it may play a role in regulating response to platinum-based chemotherapy in the treatment of EOC.
Authors: Judit Moldvay; Katalin Fábián; Márta Jäckel; Zsuzsanna Németh; Krisztina Bogos; József Furák; László Tiszlavicz; János Fillinger; Balázs Döme; Zsuzsa Schaff Journal: Pathol Oncol Res Date: 2016-09-29 Impact factor: 3.201
Authors: C H Choi; J-J Choi; Y-A Park; Y-Y Lee; S Y Song; C O Sung; T Song; M-K Kim; T-J Kim; J-W Lee; H-J Kim; D-S Bae; B-G Kim Journal: Br J Cancer Date: 2012-05-29 Impact factor: 7.640